Goodwin’s Asia practice has been recognized for excellence across numerous practice areas and geographies. The China Business Law Journal has honored Goodwin with three China Business Law Awards for 2020, highlighting the firm’s impressive capabilities in Healthcare, Pharma & Life Sciences, Private Equity & Venture Capital, and Technology & Telecom.
The China Business Law Journal also recognized Goodwin for its work representing Ascentage Pharma during its initial public offering, which was selected a 2019 Deal of the Year, and named partner and Hong Kong office chair Yash Rana to its 2019 International A-List of elite lawyers for China-related matters.
The India Business Law Journal recognized Goodwin for its representation of international private equity firms in their investments in Swiggy, selecting it as a 2019 Deal of the Year. The publication also named Rana to its 2020 International A-List, which profiles the top India-focused legal experts.
Recently, Goodwin has been shortlisted by the 2020 Asia Legal Awards for M&A Firm of the Year (Medium-sized deal under $500M) and North Asia M&A Deal of the Year for its work throughout BeiGene’s global strategic oncology collaboration with Amgen.
With a strong team of multilingual lawyers qualified in the PRC, Hong Kong, India, England and the United States, Goodwin’s Asia practice has been named a leading law firm for Private Equity in Hong Kong and China by IFLR 1000 2020 and a standout firm for Corporate M&A, Private Equity, and Investment Funds in Hong Kong by Legal 500 Asia Pacific 2020.
Chambers Asia-Pacific 2020 has recognized Goodwin for excellence in Corporate/M&A: Private Equity in the Asia-Pacific region, Private Equity: Buyouts & Venture Capital Investment in China, and Corporate M&A in India. Chambers Global 2020 also recognized Goodwin as an elite firm for Corporate M&A in India.